BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Milei Threatens Falkland Oil Firms With Sanctions 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Add as a preferred source on Google
WALTHAM, Mass., March 06, 2018 -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company management will present at the following upcoming investor conferences:
- Cowen and Company 38th Annual Health Care Conference in Boston, MA on Monday, March 12, 2018 at 12:00 pm ET; and
- Oppenheimer 28th Annual Healthcare Conference in New York, NY on Wednesday, March 21, 2018 at 3:55 pm ET.
About Proteon Therapeutics
Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon's lead product candidate, vonapanitase, is an investigational drug intended to improve hemodialysis vascular access outcomes. Proteon has completed enrollment in PATENCY-2, a Phase 3 clinical trial evaluating vonapanitase in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula for hemodialysis. Proteon is also evaluating vonapanitase in a Phase 1 clinical trial in patients with peripheral artery disease (PAD). For more information, please visit www.proteontx.com.
Investor Contact
George Eldridge, Proteon Therapeutics, Senior Vice President and Chief Financial Officer
781-890-0102
[email protected]
Media Contact
Ann Stanesa, Ten Bridge Communications
617-230-0347
[email protected]
